
On January 20–21, the partners of the HYPIEND project gathered in Leuven, Belgium, for a General Assembly hosted by KU Leuven. During the meeting, significant progress was made in planning perinatal and prepubertal interventional studies, advancing the development of an innovative digital application, and defining future dissemination actions to engage the scientific community and the general public.
This month marks the first anniversary of the HYPIEND project, a significant milestone in its mission to understand and prevent the impact of endocrine-disrupting chemicals (EDCs) on vulnerable populations.
HYPIEND focuses on mitigating the effects of EDCs during critical developmental stages such as pregnancy, infancy, and breastfeeding. These substances, known to disrupt the neuroendocrine system, pose serious health risks. The project aims to identify the most harmful exposures, develop preventive strategies, and provide tools to minimize the associated risks effectively.
By fostering collaboration among leading European institutions, HYPIEND is taking significant strides toward improving health outcomes and protecting future generations from the adverse effects of EDCs.

The HYPIEND consortium is made up of 14 partners from eight European countries. They are the Eurecat Technology Centre, the project’s coordinator, the Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP-CERCA), the University of Granada, ProtoQSAR and the Health Research Institute Hospital La Fe (IIS La Fe) in Spain; Stichting Radboud University (SRU) in the Netherlands; Sciensano, the KU Leuven and the University of Liege (ULiège) in Belgium; KTH Royal Institute of Technology in Sweden; the Centre of Postgraduate Medical Education (CMKP) in Poland; and Enco SRL in Italy. King’s College London (UK) and the University of Geneva (Switzerland) are also participating.
The project, initiated in January 2024 celebrates this month their first anniversary.